Brokerages Set DarioHealth Corp. (NASDAQ:DRIO) Price Target at $32.00

Shares of DarioHealth Corp. (NASDAQ:DRIO) have received a consensus rating of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $32.00.

A number of equities research analysts recently weighed in on the stock. Cowen reaffirmed a “hold” rating on shares of DarioHealth in a research report on Friday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of DarioHealth in a research note on Monday, December 29th. Wall Street Zen cut DarioHealth from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Stifel Nicolaus set a $16.00 price target on DarioHealth in a report on Friday, November 14th.

DarioHealth Price Performance

Shares of NASDAQ DRIO opened at $12.55 on Friday. The company has a current ratio of 4.55, a quick ratio of 4.02 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $84.84 million, a price-to-earnings ratio of -1.12 and a beta of 1.05. DarioHealth has a twelve month low of $5.93 and a twelve month high of $31.00. The business has a 50 day simple moving average of $12.19 and a 200-day simple moving average of $12.15.

Institutional Investors Weigh In On DarioHealth

An institutional investor recently raised its position in DarioHealth stock. XTX Topco Ltd grew its stake in shares of DarioHealth Corp. (NASDAQ:DRIO) by 229.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 62,511 shares of the company’s stock after acquiring an additional 43,513 shares during the period. XTX Topco Ltd owned about 0.14% of DarioHealth worth $42,000 at the end of the most recent reporting period. 33.39% of the stock is currently owned by institutional investors and hedge funds.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.